Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06021769 · ClinicalTrials.gov registry record
Pessary Experience Study
A clinical trial of Pelvic Organ Prolapse and Stress Urinary Incontinence, sponsored by University of Virginia.
- Recruiting
- Registry status
- 30
- Enrollment target
- 1
- Study location
NCT06021769: Recruiting study of Pelvic Organ Prolapse and Stress Urinary Incontinence, sponsored by University of Virginia.
NCT06021769 is a study of Pelvic Organ Prolapse and Stress Urinary Incontinence that is actively recruiting participants, run by University of Virginia. The registered enrollment target is 30 participants, below the 144-participant average among 40 other Pelvic Organ Prolapse trials with a reported enrollment target (79% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06021769, a study of Pelvic Organ Prolapse and Stress Urinary Incontinence, is actively recruiting participants, sponsored by University of Virginia.
- RECRUITING
- Registry status
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
Pessaries are silicone devices inserted into the vagina for treatment of pelvic organ prolapse or stress urinary incontinence. They are adequate treatment options for patients who are poor surgical candidates, those who decline surgical intervention, or as a temporizing measure in those ultimately planning surgery. Most studies suggest that about 75% of patients are able to be successfully fit with a pessary, but about 50% discontinue pessary use within 12 months of initiation. The purpose of this study is to determine why pessaries are discontinued.
Primary Outcome
Perform a patient-centered, qualitative analysis of pessary discontinuation
Conditions Studied
Interventions
- OTHER Observational only
Study Locations (1)
Virginia
- University of Virginia - Charlottesville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2023-06-12 |
| Est. Completion | 2026-12 |
What NCT06021769 shows while recruiting
NCT06021769 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 144-participant average among 40 other Pelvic Organ Prolapse trials with a reported enrollment target (79% lower).
The record links to 2 conditions, with Pelvic Organ Prolapse appearing as the primary indexed condition, and to 1 intervention - of which Observational only is the first listed.
NCT06021769 reports a single indexed study location in Virginia.
Frequently Asked Questions
What is clinical trial NCT06021769 about?
NCT06021769 is a clinical study titled "Pessary Experience Study". Pessaries are silicone devices inserted into the vagina for treatment of pelvic organ prolapse or stress urinary incontinence. They are adequate treatment options for patients who are poor surgical candidates, those who decline surgical intervention, or as a temporizing measure in those ultimately p...
What is the current status of trial NCT06021769?
This trial is currently recruiting. The enrollment target is 30 participants. The study started on 2023-06-12. Estimated completion is 2026-12.
What conditions does trial NCT06021769 study?
This clinical trial studies the following conditions: Pelvic Organ Prolapse, Stress Urinary Incontinence.
What interventions are being tested in trial NCT06021769?
The interventions under investigation include: Observational only (OTHER).
Who is sponsoring clinical trial NCT06021769?
This trial is sponsored by University of Virginia, which has 449 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06021769 being conducted?
This trial has 1 study location across Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pelvic Organ Prolapse
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06021769's enrollment target sits among peer trials
30 39th of 40 higher than 1 of 40 other Pelvic Organ Prolapse trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Pelvic Organ Prolapse trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Centered Surgery - Preoperative Counseling and Patient Satisfaction
RECRUITING
-
Ethicon Pelvic Mesh Post Market Clinical Follow-up Registry
RECRUITING
-
SORE Study: Sitz Baths After Urogynecologic Reconstruction
RECRUITING · NA
-
POMEGRANATE Trial: Comparing Reia Pessary Versus Standard of Care Pessary for Pelvic Organ Prolapse Treatment
RECRUITING · NA
-
Sequence of Midurethral Sling Placement During Robotic Sacrocolpopexy
RECRUITING · NA
-
The AccelERate Trial
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI